{
    "id": 3069,
    "name": "astrocytoma",
    "source": "DOID",
    "definition": "A malignant glioma that is has_material_basis_in astrocyte cells, a type of star-shaped glial cell, located in the brain and spinal cord. [url:http\\://en.wikipedia.org/wiki/Astrocytoma, url:http\\://www.cancer.org/Cancer/BrainCNSTumorsinAdults/DetailedGuide/brain-and-spinal-cord-tumors-in-adults-what-are-brain-spinal-tumors]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "4861"
    ],
    "termId": "DOID:3069",
    "evidence": [
        {
            "id": 9042,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Veliparib (ABT-888) had a very limited effect on the cell viability of multiple cultured pediatric high grade astrocytoma cell lines (PMID: 26351319).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6886,
                    "pubMedId": 26351319,
                    "title": "Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9044,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) resulted in decreased cell viability of some pediatric high grade astrocytoma cell lines in culture (PMID: 26351319).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6886,
                    "pubMedId": 26351319,
                    "title": "Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351319"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9046,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pediatric high grade astrocytoma cell lines treated with Zejula (niraparib) demonstrated decreased cell viability and proliferation in culture, and a small survival benefit in xenograft models (PMID: 26351319).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6886,
                    "pubMedId": 26351319,
                    "title": "Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351319"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9047,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a pediatric high grade astrocytoma cell line treated with a combination of ionizing radiation and Zejula (niraparib) demonstrated a greater reduction in cell survival in culture and a better survival benefit in xenograft models compared to either agent alone (PMID: 26351319).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4866,
                "therapyName": "Niraparib + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6886,
                    "pubMedId": 26351319,
                    "title": "Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351319"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11063,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination of BEZ235 and Afinitor (everolimus) resulted in stable disease in a patient with astrocytoma (PMID: 28357727).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1321,
                "therapyName": "BEZ235 + Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9058,
                    "pubMedId": 28357727,
                    "title": "A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28357727"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13381,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "IDH1 mutations aid in the diagnosis of grade II and grade III astrocytomas (NCCN.org).",
            "molecularProfile": {
                "id": 1781,
                "profileName": "IDH1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13384,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "ATRX deficiency in combination with IDH mutation aids in the diagnosis of astrocytoma (NCCN.org).",
            "molecularProfile": {
                "id": 22833,
                "profileName": "ATRX loss IDH1 mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13389,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "ATRX deficiency in combination with IDH mutation aids in the diagnosis of astrocytoma (NCCN.org).",
            "molecularProfile": {
                "id": 29113,
                "profileName": "ATRX loss IDH2 mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13398,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "IDH2 mutations aid in the diagnosis of grade II and grade III astrocytomas (NCCN.org).",
            "molecularProfile": {
                "id": 5912,
                "profileName": "IDH2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13771,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "The combination of IDH mutation and lack of TERT mutation aids in the diagnosis of astrocytoma (NCCN.org).",
            "molecularProfile": {
                "id": 29410,
                "profileName": "IDH1 mut TERT wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13772,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "The combination of IDH mutation and lack of TERT mutation aids in the diagnosis of astrocytoma (NCCN.org).",
            "molecularProfile": {
                "id": 29411,
                "profileName": "IDH2 mut TERT wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18430,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 treatment results in increased soft agar growth of transformed mouse astrocytes expressing QKI-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18431,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX8394 treatment results in increased soft agar growth of transformed mouse astrocytes expressing QKI-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18432,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 treatment resulted in paradoxical activation of the MAPK pathway and increased soft agar growth in transformed mouse astrocytes expressing SRGAP3-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 15349,
                "profileName": "SRGAP3 - RAF1"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18433,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX8394 treatment resulted in paradoxical activation of the MAPK pathway and increased soft agar growth in transformed mouse astrocytes expressing SRGAP3-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 15349,
                "profileName": "SRGAP3 - RAF1"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18435,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited MAPK and PI3K signaling, resulted in inhibition of soft agar growth in transformed mouse astrocytes expressing QKI-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18436,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited MAPK and PI3K signaling, resulted in inhibition of soft agar growth in transformed mouse astrocytes expressing SRGAP3-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 15349,
                "profileName": "SRGAP3 - RAF1"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18440,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation and soft agar growth in transformed mouse astrocytes expressing QKI-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18441,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation and soft agar growth in transformed mouse astrocytes expressing SRGAP3-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 15349,
                "profileName": "SRGAP3 - RAF1"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18445,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Afinitor (everolimus) combination treatment inhibited MAPK and PI3K signaling, resulted in suppression of soft agar growth in transformed mouse astrocytes expressing QKI-RAF1 in culture, and prolonged tumor suppression in xenograft models (PMID: 28806393).",
            "molecularProfile": {
                "id": 32710,
                "profileName": "QKI - RAF1"
            },
            "therapy": {
                "id": 1271,
                "therapyName": "Everolimus + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18991,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) reduced viability of transformed human astrocytes expressing CCDC88A-ALK in culture (PMID: 31554817).",
            "molecularProfile": {
                "id": 23674,
                "profileName": "CCDC88A - ALK"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16496,
                    "pubMedId": 31554817,
                    "title": "Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31554817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18992,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) reduced viability of transformed human astrocytes expressing CCDC88A-ALK in culture (PMID: 31554817).",
            "molecularProfile": {
                "id": 23674,
                "profileName": "CCDC88A - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16496,
                    "pubMedId": 31554817,
                    "title": "Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31554817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00301418",
            "title": "Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4,
                    "therapyName": "Erlotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00492687",
            "title": "Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1456,
                    "therapyName": "Tamoxifen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00906516",
            "title": "Neuradiab Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2146,
                    "therapyName": "81C6 + Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00968240",
            "title": "Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01052363",
            "title": "OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2109,
                    "therapyName": "Bevacizumab + Fosbretabulin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01130077",
            "title": "A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2595,
                    "therapyName": "Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01140568",
            "title": "Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 829,
                    "therapyName": "Nilotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01188096",
            "title": "A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2595,
                    "therapyName": "Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01238237",
            "title": "Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 694,
                    "therapyName": "Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01266031",
            "title": "Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2110,
                    "therapyName": "Bevacizumab + Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01269853",
            "title": "Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01331135",
            "title": "Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01339039",
            "title": "Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2120,
                    "therapyName": "Bevacizumab + Plerixafor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01386710",
            "title": "Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 2074,
                    "therapyName": "Bevacizumab + Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01392209",
            "title": "Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01403610",
            "title": "Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2144,
                    "therapyName": "Bevacizumab + Evofosfamide",
                    "synonyms": null
                },
                {
                    "id": 1317,
                    "therapyName": "Evofosfamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01434602",
            "title": "Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2299,
                    "therapyName": "Everolimus + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01607905",
            "title": "Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01721577",
            "title": "Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2745,
                    "therapyName": "AXL1717",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01734512",
            "title": "PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01884740",
            "title": "Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1654,
                    "therapyName": "Bevacizumab + Cetuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01891747",
            "title": "A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2115,
                    "therapyName": "Bevacizumab + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01999270",
            "title": "Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2112,
                    "therapyName": "Bevacizumab + Irinotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02100891",
            "title": "Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT02101905",
            "title": "Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 787,
                    "therapyName": "Lapatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02238496",
            "title": "Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2194,
                    "therapyName": "Perifosine + Temsirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02372006",
            "title": "Trial of Afatinib in Pediatric Tumours",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02423525",
            "title": "Safety Study of Afatinib for Brain Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02490930",
            "title": "A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3610,
                    "therapyName": "Fingolimod",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02529072",
            "title": "Nivolumab With DC Vaccines for Recurrent Brain Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02549833",
            "title": "Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9775,
                    "therapyName": "GBM6-AD lysate protein vaccine + Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02607124",
            "title": "Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 790,
                    "therapyName": "Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02885324",
            "title": "Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02924038",
            "title": "A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4835,
                    "therapyName": "IMA950 + Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 2525,
                    "therapyName": "Varlilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02942264",
            "title": "TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5836,
                    "therapyName": "TG02",
                    "synonyms": null
                },
                {
                    "id": 5851,
                    "therapyName": "Temozolomide + TG02",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03011671",
            "title": "Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9029,
                    "therapyName": "Acetazolamide + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03032484",
            "title": "TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 5260,
                    "therapyName": "Bevacizumab + TVB-2640",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03220646",
            "title": "The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03295396",
            "title": "ONC201 in Adults With Recurrent High-grade Glioma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1687,
                    "therapyName": "ONC201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03332355",
            "title": "Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6443,
                    "therapyName": "PAC-1 + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03343197",
            "title": "Study of AG-120 and AG-881 in Subjects With Low Grade Glioma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1491,
                    "therapyName": "Ivosidenib",
                    "synonyms": null
                },
                {
                    "id": 2995,
                    "therapyName": "AG-881",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03514069",
            "title": "Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                },
                {
                    "id": 6913,
                    "therapyName": "Ruxolitinib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03528642",
            "title": "CB-839 With Radiation Therapy and Temozolomide in Treating Participants With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9567,
                    "therapyName": "CB-839 + Radiotherapy + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03532295",
            "title": "Epacadostat in Combination With Radiation Therapy and Avelumab in Patients With Recurrent Gliomas",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 6953,
                    "therapyName": "Avelumab + Bevacizumab + Epacadostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03596086",
            "title": "HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7303,
                    "therapyName": "HSV-Tk + Valacyclovir",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03603405",
            "title": "HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7040,
                    "therapyName": "HSV-Tk",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03605550",
            "title": "A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5407,
                    "therapyName": "PTC596",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03696355",
            "title": "Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2018,
                    "therapyName": "GDC-0084",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03871257",
            "title": "A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8990,
                    "therapyName": "Carboplatin + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03896568",
            "title": "Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4407,
                    "therapyName": "DNX-2401",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03919071",
            "title": "Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03975829",
            "title": "Pediatric Long-Term Follow-up and Rollover Study",
            "phase": "FDA approved",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04164901",
            "title": "Study of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2995,
                    "therapyName": "AG-881",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04166409",
            "title": "A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                {
                    "id": 8990,
                    "therapyName": "Carboplatin + Vincristine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04197934",
            "title": "WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8206,
                    "therapyName": "WSD0922",
                    "synonyms": null
                }
            ]
        }
    ]
}